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AT A GLANCE COMMENTARY
Miyata Y, et al.
Background
Heme oxygenase (HO)-1 is up-regulated in malig-
nancies and, in turn, regulates various cancer-
related factors and molecules. In addition, HO-1
expression has been associated with cigarette
smoking. However, little is known about its smok-
ing-related function in bladder cancer.
Translational Significance
In this manuscript, we demonstrated that HO-1 was
up-regulated by smoking and was associated with
malignant behavior including cancer cell prolifer-
ation, lymphangiogenesis, and expression of
VEGF-D, COX-2, and MMP-2. These patholog-
ical roles of HO-1 in bladder cancer were regulated
by a complex mechanism that depended on smok-
ing intensity.
Translational Research
Volume 164, Number 6 Miyata et al 469INTRODUCTION
Angiogenesis and lymphangiogenesis are important
for tumor growth and cell dissemination in nearly all
solid tumors including urothelial cancer (UC).1,2 In
fact, tumor-associated angiogenesis and lymphangio-
genesis are closely correlated with survival in patients
with UC.3 Moreover, cancer cell proliferation and inva-
sion crucially mediate outcomes in these patients.4,5
Vascular endothelial growth factors (VEGFs) are well-
known mediators of angiogenesis and lymphan-
giogenesis under pathologic conditions. In the past,
VEGF-Awas thought to be important for angiogenesis,
whereas VEGF-C was thought to be important for lym-
phangiogenesis. However, recent studies have demon-
strated that VEGFs are not limited to these specific
pathologic roles. VEGF-A has been associated with
lymphangiogenesis,6 and VEGF-C can stimulate lym-
phangiogenesis under various pathologic conditions.7
In addition, VEGF-D expression has been positively
associated with lymphangiogenesis in cancer tissues.3
Cyclooxygenase (COX)-2 is a well-known angiogen-
esis-related molecule.8 COX-2 also functions in tumor
growth, progression, and survival in patients with
bladder cancer.9 Furthermore, matrix metalloproteinase
(MMP)-2 and MMP-9 are closely associated with can-
cer cell invasion and metastasis in various cancers.10,11
Elucidating the regulatory mechanism of these cancer-
related factors is essential for identifying predictivemarkers and potential therapeutic targets in bladder
cancer.
Cigarette smoking is an important risk factor for UC,
especially in the developed world.12 Interestingly, the
cancer-related molecules mentioned previously have
also been associated with smoking.13-15 There is a
general agreement that smoking positively correlates
with tumor aggressiveness in many malignancies.
However, it remains unclear how smoking regulates
the expression of VEGFs, COX-2, andMMPs in patients
with bladder cancer.
In the present study, we focused on heme oxygenase
(HO)-1 for the following reasons: (1) HO-1 regulates
the expression of VEGF-A, COX-2, and MMPs under
various pathologic conditions16-18; (2) HO-1 is associ-
ated with features of tumor aggressiveness, including
angiogenesis and cell proliferation19-21; and (3) ciga-
rette smoking induces HO-1 expression in a variety of
cancer cells.17,22 Therefore, the main aim of this study
was to clarify the changes of pathologic significance
and predictive roles of HO-1 expression with respect to
smoking status in patients with bladder cancer. Further-
more, we tested the hypothesis that smoking intensity
is correlated with angiogenesis, lymphangiogenesis,
and cancer cell proliferation via the regulation of
VEGF-A, VEGF-C, VEGF-D, COX-2, MMP-2, and
MMP-9 in human bladder cancer tissues.
MATERIALS AND METHODS
Patients and tissue samples. Two hundred fifteen
consecutive patients who were diagnosed with bladder
cancer were reviewed retrospectively. Our study in-
cluded 166 men (77.2%) and 49 women (22.8%), and
their mean age at diagnosis was 68.6 years (standard
deviation [SD], 11.6; median, 70). Patients who had
received any preoperative therapy, such as chemotherapy
and/or radiotherapy, were excluded from the study. In
addition, tumors with squamous cell carcinoma and/or
adenocarcinoma were excluded regardless of pure and
a part of tumor from this study. All histologic diagnoses
were performed using formalin-fixed and paraffin-
embedded specimens. Staging and grade was assessed
in accordance with the 2002 tumor-node-metastasis
classification and the 2004 World Health Organization
grading system. A single pathologist performed all
pathologic examinations. The median follow-up period
was 60.9 months (range, 3–256 months). We explained
the purpose, methods, and right to refuse all patients in
writing, and we obtained informed consent in writing.
The study protocol, including methods of informed
consent and protection of personal information, was
approved by the Human Ethics Review Committee of
Nagasaki University Hospital.
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were deparaffinized stepwise in xylene and rehydrated
in ethanol. Antigen retrieval was performed at 121C
for 15 minutes or 95C for 40 minutes in 0.01M sodium
citrate buffer (pH 6.0) for either the anti-Ki-67 antibody
or all other antibodies, respectively. All sections were
immersed in 3% hydrogen peroxide for 30 minutes.
Primary antibodies were obtained from Enzo Life
Sciences Inc (Farmingdale, NY; for HO-1, #ADI-SPA-
896-F), DakoCytomation (Glostrup, Denmark; for Ki-
67, #M7240, CD34, #M7145, and D2-40, #M3619),
Santa Cruz Biotechnology Inc (Santa Cruz, CA; for
VEGF-A, #sc-152), Zymed Laboratories (San Fran-
cisco, CA; for VEGF-C, #18-2255), R&D systems Inc
(Abingdon, UK; for VEGF-D, #MAB286), Immuno-
Biological Laboratories (Gunnma, Japan; for COX-2,
#18515), and Daiich Fine Chemical (Toyama, Japan;
for MMP-2, #F-73 and -9, #F-69). Sections were
incubated at 4C overnight. Then, sections were
treated with peroxidase using the labeled polymer
method with DAKO EnVision1 Peroxidase (Dako
Corporation, Carpinteria, CA; #K4001 for anti-mouse
and K4003 for anti-rabbit) for 60 minutes. The
peroxidase reaction was visualized using the liquid
3,3’-Diaminobenzidine, tetrahydrochloride (DAB)
substrate kit (Zymed Laboratories Inc, San Francisco;
CA, #00-2014). Sections were counterstained with
hematoxylin before mounting. A consecutive section
from each sample processed without the primary
antibody was used as a negative control.
Immunohistochemical staining of a positive control was
performed as described previously for all antibodies
except HO-1.2,3,8,10 Briefly, positive control samples in-
cluded tissues from colon cancer (VEGF-A, VEGF-C,
and VEGF-D as well as MMP-2 and MMP-9), renal
cell carcinoma (COX-2), renal vein (CD34), and tonsil
(D2-40 and Ki-67). For HO-1, spleen was used as
positive control, and the antibody was added according
to the manufacturer’s data sheet.
Quantitative analysis and staining interpretation. For
evaluation of HO-1 expression, immunostained sections
were scored semiquantitatively based on the proportion
of tumor cells stained and the staining intensity, as pre-
viously described.23 Briefly, all specimens were asses-
sed using the immunoreactive score (IRS), which was
calculated by multiplying the staining intensity (grade
0 5 none, 1 5 weak, 2 5 moderate, and 3 5 strong)
by the percentage of positively stained cells (0, ,5.0%;
1, 5%–25%; 2, 26%–50%; 3, .51%). To determine the
microvessel density (MVD) and lymph vessel density
(LVD), tumor sections were stained with anti-CD34
antibody and anti-D2-40-antibody, respectively. For
each tumor section, 3–5 fields with the greatest density
of positively stained vessels, referred to as ‘‘hot spots,’’were evaluated, irrespective of the tumor region. MVD
was defined as the number of positively stained vessels
per high-power field (magnification, 3200). The pro-
liferation index (PI) represented the percentage of
Ki-67–positive cells. For HO-1 staining, MVD, LVD,
and PI, samples with staining greater than the median
value were categorized as high, and those with staining
less than or equal to the median value were categorized
as low. For other factors, immunoreactive staining was
evaluated using the semiquantitative method. Briefly,
staining intensity was graded as none, weak, moderate,
or strong. Cancer cells with moderate or strong staining
were considered positively stained cells. Samples with
values above the median were categorized into the high
group, and those with staining less than or equal to the
median value were categorized into the low group. The
mean percentages in 3–7 randomly chosen fields, and
in at least 500 cancer cells, were examined. Slides were
examined using an E-400 microscope (Nikon, Tokyo,
Japan) to produce digital images, which were examined
using a computer-aided image analysis system (Win
ROOF version 5.0; MITANI, Fukui, Japan). Slides
were evaluated twice at different times by 2 inves-
tigators (Y.M. and S.K.), who were blinded to the
clinicopathologic features and survival data.
Definition of smoking status. All patients were inter-
viewed in person regarding smoking history at diagnosis.
A patient was classified as a smoker based on a previously
reported approach.23 Briefly, if patient smoked at least
1 cigarette daily for 6 months or longer, he/she was
considered an ever smoker. In addition, patients were
divided into 3 groups, according to the combination of
smoking duration and cigarettes per day, as follows:
group 1, nonsmokers or patients who smoked ,20
cigarettes per day for #30 years (n 5 102); group 2,
patients who smoked for 31–40 years or .20 cigarettes
per day for #30 years (n 5 60); and group 3, patients
who smoked for .40 years (n 5 53). Smoking index
was calculated by multiplying the smoking duration and
the number of cigarettes per day.
Statistical analysis. Results were expressed as medians
and interquartile range (IQR) unless otherwise speci-
fied. The Mann-Whitney U test was performed for
continuous variables, and the chi-square test was used
for categorical comparison of data. The crude and
adjusted effects were estimated by logistic regression
analysis and are reported as odds ratios (ORs) with
95% confidence intervals (CIs) together with the
P values. Variables that achieved statistical
significance in a univariate analysis were subsequently
entered into a multivariate analysis model. Cause-
specific survival rates were compared with Kaplan-
Meier analysis and the log rank test. COX
proportional hazards analysis was described as hazard
Table I. HO-1 expression and clinicopathologic
features
Number
HO-1 expression
Negative; Positive;
Fig 1. Representative examples of HO-1 expression in bladder cancer tissues. HO-1 expression was mainly
detected in cytoplasm of cancer cells (A). Some stromal cells and nuclei of cancer cells were positively stained
for HO-1 (B). Finally, 120 of 215 (55.0%) patients were judged as positive according to the scoring system based
on the proportion of tumor cells stained and their staining intensity. HO, heme oxygenase.
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statistical tests were 2-sided, and significance was
defined as P , 0.05. All statistical analyses were
performed using the statistical package StatView
(version 5.0; Abacus Concept, Inc, CA).n 5 215 P valuen 5 95 n 5 120
T stage; n (%) 0.008
Ta 60 36 (60.0) 24 (40.0)
T1 92 40 (43.5) 52 (56.5)
T2 31 9 (29.0) 22 (71.0)
T3 22 9 (40.9) 14 (59.1)
T4 10 1 (10.0) 9 (90.0)
Ta and 1 152 76 (50.0) 76 (50.0) 0.008
T2–4 63 19 (30.2) 44 (69.8)
N stage 0.022
N0 198 92 (46.5) 106 (53.5)
N1 1 2 17 3 (11.7) 14 (82.4)
M stage 0.070
M0 195 90 (46.2) 105 (53.8)
M1 20 5 (25.0) 15 (75.0)
Grade 0.031
Low 100 52 (52.0) 48 (48.0)
High 115 43 (37.4) 72 (62.6)
Abbreviation: HO, heme oxygenase.RESULTS
HO-1 expression and clinicopathologic features. HO-1
expression was mainly detected in the cytoplasm of can-
cer cells, although nuclear staining was detected in
some specimens. Some stromal cells, such as fibro-
blasts, tumor-infiltrating cells, and endothelial cells,
also stained positively for HO-1 (Fig 1, A and B). The
mean IRS was 4.0 (SD, 2.9; median, 4; IQR, 2–6),
and samples were considered positive when the IRS
was $4. Finally, 120 of 215 (55.0%) patients were
judged to have tumors with positive expression.
There was no significant correlation between HO-1
expression and age at diagnosis (P 5 0.199). On the
contrary, there was a significantly higher percentage
of HO-1 positivity in males (59.6%) than in females
(42.9%) (P 5 0.038). Relationships between HO-1
expression and pathologic features are shown in
Table I. High T stage (T2–4) correlated with higher per-
centage of HO-1 positivity compared with low T stage
(P5 0.008). Similarly, positive staining of HO-1 in pa-
tients with lymph node metastasis was significantly
higher (P5 0.022) than those without. On the contrary,
HO-1 staining was not associated with distant metas-
tasis. For tumor grade, a significant correlation was
found with significant difference (P 5 0.031).
Relationship between smoking status and HO-1
expression. The mean IRS for HO-1 in ever smokers
(n 5 125; mean, 4.8; SD, 6.1; median, 4; IQR, 3–6)
was significantly higher (P , 0.001) than that in never
smokers (n 5 90; mean, 2.9; SD, 3.1; median, 3; IQR,
1–4). When group 1 was divided into 2 subgroups,
never and light smokers (smoked #20 cigarettes perday for #30 years), the HO-1 IRS tended to be higher
in light smokers (mean, 3.2; SD, 2.0; median, 3; IQR,
2–4) than in never smokers (mean, 2.8; SD, 1.7;
median, 3; IQR, 1–4). However, this difference was
not statistically significant (P 5 0.400), similar to the
results in a previous report.24 The HO-1 IRS in the 3
groups and the correlation between HO-1 IRS and
smoking index are shown in Fig 2, A and B. Fur-
thermore, HO-1 expression and smoking in moderate
(group 2) and heavy (group 3) smokers were signi-
ficantly different when compared with that of never or
light smokers (group 1) (group 2: OR, 3.15; 95% CI,
1.47–6.73; P 5 0.003; group 3: OR, 2.66; 95% CI,
1.24–5.70; P 5 0.012) using multivariate analyses
including gender and all pathologic features.
Fig 2. Higher smoking intensity was significantly associated with the HO-1 immunoreactive score (A). A similar
finding was also found when correlating other parameters with smoking intensity, which equals the smoking dura-
tion multiplied by the number of cigarettes per day (B). The confidence limits in the box plots are overlapping (A)
and the r value is modest (B). Therefore, although HO-1 expression was significantly correlated to smoking in-
tensity, such statistical significant differences and correlations between data are not really strong.
Table II. Relationship between HO-1 expression and
cancer-related factors
All patients
(n 5 215)
Smoking status (odds ratio/P value)
Group1 Group 2 Group 3
Univariate analysis
VEGF-A 1.19/0.532 0.98/0.943 1.42/0.541 1.32/0.630
VEGF-C 1.12/0.692 0.57/0.174 3.42/0.040 1.18/0.776
VEGF-D 3.28/,0.001 2.48/0.035 4.71/0.011 1.53/0.471
COX-2 2.92/,0.001 2.57/0.242 4.23/0.017 1.50/0.488
MMP-2 2.83/,0.001 2.94/0.001 6.20/0.004 0.85/0.781
MMP-9 2.85/,0.001 2.75/0.017 3.27/0.048 1.32/0.630
MVD 1.41/0.218 1.07/0.868 2.55/0.116 1.50/0.488
LVD 2.67/,0.001 1.65/0.225 7.92/0.001 1.20/0.756
PI 3.57/,0.001 2.48/0.028 4.05/0.024 6.50/0.004
Multivariate analysis*
VEGF-A — — — —
VEGF-C — — 1.70/0.411 —
VEGF-D 3.07/,0.001 2.63/0.034 3.37/0.077 —
COX-2 2.48/0.002 2.40/0.048 2.58/0.161 —
MMP-2 2.42/0.004 2.98/0.015 6.30/0.027 —
MMP-9 2.25/0.010 — 1.86/0.376 —
MVD — — — —
LVD 2.22/0.007 1.49/0.363 6.11/0.013 —
PI 2.90/,0.001 2.41/0.062 2.07/0.309 6.67/0.007
Abbreviations:COX, cyclooxygenase; HO, heme oxygenase; LVD,
lymph vessel density; MMP, matrix metalloproteinase; MVD, micro-
vessel density; PI, proliferation index; VEGF, vascular endothelial
growth factor.
*Adjusted by tumor-node-metastasis stage and grade.
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related factors. As shown in Table II, univariate
analyses showed that the IRS of HO-1 significantly
correlated with the expression levels of VEGF-D,
COX-2, MMP-2, and MMP-9 as well as LVD and PI
(P , 0.001). In addition, these significant correlations
depended on smoking status. For example, VEGF-C
expression and LVD were significantly correlated with
HO-1 expression in only group 2. Using multivariate
logistic regression analyses to generate a model that
included gender and all pathologic features, HO-1
expression was independently associated with the ex-
pression of MMP-2 in both groups 1 and 2. Further-
more, HO-1 expression was independently correlated
with expression of VEGF-D and COX-2 in group 1,
LVD in group 2, and PI in group 3.
Survival analyses. HO-1 expression was significan-
tly associated with subsequent metastasis (log rank
P 5 0.008) and cause-specific survival (log rank
P , 0.001), whereas urinary tract recurrence was not
(log rank P 5 0.095). In univariate logistic regression
analyses, radical cystectomy, tumor-node-metastasis
stage, high grade, and HO-1 expression were significan-
tly correlated with subsequent metastasis (Table III).
However, HO-1 expression was not a significant inde-
pendent predictor using multivariate analysis (HR,
1.76; 95% CI, 0.8–3.7; P 5 0.139). On the other
hand, as shown in Table IV, HO-1 expression was inde-
pendently associated with cause-specific survival in
a multivariate analysis model (HR, 3.13; 95% CI,
1.7–7.7; P 5 0.013).
Survival rates of patients in groups 1, 2, and 3 are
shown in Table V. Positive expression of HO-1 was a
significant predictor of subsequent recurrence in the
urinary tract for group 1 only. Likewise, positive
expression of HO-1 was significantly associated with
a high frequency of subsequent metastasis and poor
cause-specific survival in groups 1 and 2. In addition,the 5-year survival rate of patients with HO-1-negative
tumors in group 2 was 100%. However, HO-1 expres-
sion was not a predictor of any parameter in group 3.DISCUSSION
HO is a microsomal enzyme that catalyzes the rate-
limiting step in heme catabolism.25 HO-1 has been char-
acterized as a stress-responsive protein that is induced in
Table IV. Multivariate analyses for cause-specific
survival
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Male 0.87 0.4–1.8 0.717 — — —
High age 1.46 0.8–2.8 0.248 — — —
Cystectomy 0.71 0.3–1.6 0.391 — — —
Adjuvant
therapy
1.13 0.7–1.3 0.632 — — —
T stage (T2–4) 7.17 3.7–13.9 ,0.001 2.38 1.1–5.2 0.032
N stage
(N1 1 2)
9.01 4.3–18.8 ,0.001 2.71 1.2–6.3 0.021
M stage (M1) 6.91 3.2–14.8 ,0.001 2.60 1.1–6.3 0.033
Grade (high) 6.63 2.8–15.9 ,0.001 6.16 2.0–12.2 0.001
HO-1 (positive) 5.12 2.1–12.3 ,0.001 3.13 1.3–7.7 0.013
Abbreviations: CI, confidence interval; HO, heme oxygenase; HR,
hazard ratio.
Table III. Predictive value of HO-1 expression for
subsequent metastasis
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Male 1.04 0.5–2.3 0.927 — — —
Higher age 1.34 0.7–2.6 0.316 — — —
Cystectomy 2.96 1.3–6.7 0.001 0.28 0.1–0.8 0.015
Adjuvant
therapy
1.29 0.5–3.1 0.574 — — —
T stage
(T2–4)
6.96 3.6–13.6 ,0.001 3.52 1.6–7.8 0.002
N stage
(N1 1 2)
11.50 5.7–23.0 ,0.001 7.12 2.9–17.4 ,0.001
M stage (M1) 5.50 2.5–11.9 ,0.001 1.99 0.8–4.7 0.118
Grade (high) 6.34 2.6–15.2 ,0.001 7.83 3.0–20.4 ,0.001
HO-1
(positive)
2.57 1.2–5.3 0.011 1.76 0.8–3.7 0.139
Abbreviations: CI, confidence interval; HO, heme oxygenase; HR,
hazard ratio.
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studies have demonstrated that HO-1 expression is
increased in tumors, and the upregulation may posi-
tively influence carcinogenesis, tumor aggressiveness,
and outcomes in various cancers.28,29 Conversely,
HO-1 expression has been negatively associated with
histologic differentiation, lymph node metastasis, and
survival in patients with several cancers.16,30,31 Thus,
there have been conflicting reports regarding the
clinical significance of HO-1 in cancer. In bladder can-
cer, HO-1 inhibition decreased tumor size in a mouse
xenograft model.21 In addition, HO-1 genotype distribu-
tion has been associated with stage in bladder cancer
patients.32 Furthermore, HO-1 mRNA expression was
a significant prognostic factor for recurrence and pro-
gression in patients with nonmuscle invasive bladder
cancer.33 However, the detailed pathologic role of
HO-1 in human bladder cancer remains poorly under-
stood because the previous studies were limi-
ted to patients with nonmuscle invasive bladder
cancer.21,33,34 As such, the present study is the first to
investigate the relationship between HO-1 protein
expression and muscle invasion, lymph nodemetastasis,
and distant metastasis in human bladder cancer.
Cigarette smoking is a well-established risk factor
for bladder cancer, and smoking status may affect
tumor progression and survival.24 In addition, epidemi-
ologic reports have suggested that smoking is a
possible therapeutic target for patients with recurrent
bladder cancer.35 In the present study, we focused on
HO-1 in human bladder cancer because it is upregu-
lated by smoking in several cancers and can regulate
cancer-related factors under various pathologic condi-
tions.16-22 Our results demonstrated that HO-1 expres-sion in bladder cancer significantly correlated with
expression levels of VEGF-D, COX-2, MMP-2, and
MMP-9 as well as LVD and PI, but not with MVD
or expression of VEGF-A or VEGF-C. The association
between HO-1 and cancer-related factors depends on
the methodology used and the type of malignancy.36
For example, although HO-1 was positively associated
with cancer cell proliferation in lung cancer,37 there
was a negative correlation in prostate cancer.38 In
bladder cancer, knockdown of HO-1 suppressed cancer
cell growth.39 Similar findings were also reported in
another report.40 Our results support the finding that
HO-1 is positively correlated with cancer cell prolifer-
ation in bladder cancer. In contrast, little is known
about the relationship between HO-1 and COX-2
expression in cancer.41 In patients with bladder cancer,
one study showed no significant correlation between
HO-1 and COX-2 expressions.21 However, that study’s
population consisted of only 23 specimens of high-
grade and T1 tumors. Therefore, larger and more
detailed studies are necessary to establish the correla-
tion between HO-1 and COX-2 expressions in cancers,
including bladder cancer.
Unexpectedly, HO-1 expression did not significantly
correlate with the expression of VEGF-A or VEGF-C.
In several cancers, there has been a significant posi-
tive correlation between HO-1 and VEGF-A expres-
sions.16,17 However, the opposite was found in
prostate cancer, where HO-1 expression was associated
with reduced VEGF-A expression.38 In nonmuscle inva-
sive bladder cancer specimens of bladder cancer, HO-1
expression was not correlated with VEGF-A expres-
sion.21 The results from the present study support the
conclusion that there is no relationship between HO-1
and VEGF-A expressions in bladder cancer. Our results
also showed that HO-1 expression was not significantly
Table V. Survival rates according to smoking intensity
HO-1 expression
(number of patients)
Urinary tract
recurrence—free rates (%)
Subsequent
metastasis-free rates (%)
Cause-specific
survival rates (%)
1 y 3 y 5 y 1 y 3 y 5 y 1 y 3 y 5 y
Group 1
Negative (60) 86.3 80.9 71.2 100 98.2 94.2 100 98.0 96.0
Positive (42) 70.5 56.0 46.5 97.4 83.5 76.7 97.6 78.8 76.0
Log rank P 0.014 0.012 0.001
Group 2
Negative (17) 75.0 61.1 52.4 100 100 100 100 100 100
Positive (23) 83.0 69.5 47.5 80.6 72.8 65.9 97.6 73.4 63.8
Log rank P 0.822 0.044 0.034
Group 3
Negative (18) 72.2 42.1 33.7 88.2 76.0 67.6 100 91.7 91.7
Positive (35) 74.2 60.8 48.7 97.1 90.7 85.9 97.1 93.5 89.4
Log rank P 0.222 0.220 0.412
Abbreviation: HO, heme oxygenase.
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ported that HO-1 overexpression led to the downregula-
tion of VEGF-C messenger RNA expression in prostate
cancer.42 However, there are few data on the relation-
ship between HO-1 and VEGF-C in cancer. To our
knowledge, this is the first report on the relationship
between HO-1 and VEGF-D expressions in human can-
cer, including bladder cancer. VEGF-D has been re-
ported to play important roles in cancer progression
and survival in patients with bladder cancer.3 These
findings emphasize the importance of future studies on
the relationship between HO-1 and VEGFs to develop
treatment strategies in patients with bladder cancer.
Our results demonstrated that HO-1 expression was
significantly associated with LVD, but not with MVD.
Many studies have reported that HO-1 has proangio-
genic effects in various cancers, including bladder can-
cer.17,19,21 However, several reports have suggested that
HO-1 overexpression suppressed angiogenesis and
decreased MVD under pathologic conditions including
cancer.42,43 This group suggested that the discrepancy
may be because of HO-1’s dual effect on angiogenesis
depending on cancer type, inflammatory status, and/or
other unknown factors. Although our study does not
resolve this discrepancy, we agree with their expla-
nation for the discrepant results.
Although the present study is the first report on the
relationship between HO-1 and lymphangiogenesis in
cancer, we cannot determine the mechanism by which
HO-1 regulates lymphangiogenesis in bladder can-
cer. However, a previous report showed that VEGF-D
expression was significantly associated with LVD in pa-
tients with bladder cancer.3 On the basis of our finding,
HO-1 may stimulate lymphangiogenesis via the upregu-
lation of VEGF-D in human bladder cancer tissues.MMP-2 and MMP-9 are well-known regulators of can-
cer cell migration and invasion in cancer tissues. In
addition, several studies have shown that expression
levels of MMP-2 and MMP-9 are positively associated
with HO-1 expression in a variety of cancers.44,45
Although no study has investigated the relationship
between HO-1 and the expression levels of MMP-2
andMMP-9 in bladder cancer, our results support a pos-
itive association in human bladder cancer.
One of most interesting findings in the present study
was the effect of smoking intensity on pathology and
prognosis of bladder cancer. On the basis of our finding
that HO-1 expression increased proportionally to smok-
ing intensity, we hypothesized that HO-1 would be
closely associated with malignant behavior. However,
HO-1 expression was only a significant predictor for
prognosis and survival in groups 1 and 2, but not in
group 3, which had the highest smoking intensity. In
addition, we obtained similar data on the association
between HO-1 expression and all cancer-related factors.
Although we cannot explain this discrepancy, we spec-
ulate that other factors may play more prominent roles
than HO-1 in patients with high smoking intensities.
Indeed, smoking intensity is linearly associated with
pathologic mechanisms, such as DNA damage response
and production of hydrogen peroxide, in malignant
conditions.46,47 Furthermore, the relationship between
HO-1 expression and cancer-related factors as well as
the dependency on smoking status is complex. Our
multivariate analysis showed that HO-1 expression
was significantly associated with MMP-2 expression
in groups 1 and 2. However, a similar analysis showed
that HO-1 expression was significantly associated with
VEGF-D, COX-2, LVD, and PI in groups 1, 2, and 3.
Unfortunately, our study is limited in its ability to
Translational Research
Volume 164, Number 6 Miyata et al 475elucidate these complex mechanisms because of the
relatively small number of patients in groups 2
(n 5 60) and 3 (n 5 53). Further detailed studies are
necessary to establish the smoking-related function of
HO-1 in cancer.
In recent years, HO-1 has been considered as a
therapeutic target and a predictive factor in various can-
cers.48,23 The present study provides novel information
regarding the pathologic significance and prognostic
role of HO-1 expression based on smoking status. On
the basis of our results, we propose that HO-1 can be
used as a therapeutic target and a predictor of survival
in patients with bladder cancer, except for those who
are heavy smokers. However, there are still things that
need to be further elucidated about HO-1. HO-1 was
significantly associated with cause-specific survival,
but not with distant metastasis at diagnosis or subse-
quent metastasis by multivariate analyses. Unfortunate-
ly, we cannot explain such a discrepancy. However, we
speculate that HO-1 expression does positively asso-
ciate with metastasis although, in our study, this rela-
tionship did not slightly reach statistical significance.
In addition, it is possible that HO-1 expression is not
only associated with pathologic aggressiveness, but
also with response to treatment of UC.49 Thus, to clarify
the detailed pathologic activities and prognostic roles of
HO-1 expression further, a large study is necessary for
patients with urothelial carcinoma of the upper urinary
tract (UC-UUT).CONCLUSIONS
Our study demonstrates that HO-1 expression is posi-
tively associated with smoking intensity in patients with
bladder cancer. HO-1 expression was significantly asso-
ciated with tumor growth, cancer cell progression, and
patient survival possibly by regulating various cancer-
related mechanisms, including cancer cell proliferation,
lymphangiogenesis, and the expression of VEGF-D,
COX-2, and MMP-2. Our data suggest that the patho-
logic significance and prognostic value of HO-1 depend
on smoking intensity in patients with bladder cancer.ACKNOWLEDGMENTS
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